NCT04643457View on ClinicalTrials.gov

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

April 23, 2024

Study Completion Date

June 6, 2024

Conditions

Atopic Dermatitis

Interventions

DRUG

UCB9741

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

DRUG

Intravenous Placebo

\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

DRUG

Subcutaneous Placebo

Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.

Trial Locations (10)

Unknown

Up0089 303, Pleven

Up0089 301, Sofia

Up0089 304, Sofia

Up0089 407, Berlin

Up0089 408, Heidelberg

Up0089 410, Leipzig

Up0089 201, Leiden

Up0089 104, Liverpool

Up0089 101, London

Up0089 103, Manchester

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT04643457 - A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter